Amgen signs Crohn’s disease deal with TCR biotech TScan Therapeutics

Amgen is taking a closer look at using T cells for inflammation, announcing a new deal Tuesday with TCR upstart TScan Therapeutics. The companies will team up to discover new targets for Crohn’s disease, and Amgen has the option to expand the agreement into ulcerative colitis. Amgen is paying $30…